Gain Therapeutics (NASDAQ:GANX) Rating Reiterated by HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 387.80% from the stock’s previous close.

Several other research firms also recently weighed in on GANX. Chardan Capital reissued a “buy” rating and set a $6.00 target price on shares of Gain Therapeutics in a research report on Friday, August 9th. Oppenheimer reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, August 14th.

Gain Therapeutics Price Performance

GANX stock opened at $1.64 on Tuesday. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $5.33. The firm has a market capitalization of $29.61 million, a P/E ratio of -1.09 and a beta of 0.35. The company has a fifty day simple moving average of $1.29 and a two-hundred day simple moving average of $2.05. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.03.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.11). Analysts anticipate that Gain Therapeutics will post -1.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Chairman Khalid Islam purchased 50,000 shares of the business’s stock in a transaction dated Friday, August 9th. The shares were purchased at an average cost of $1.00 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the chairman now owns 50,000 shares in the company, valued at approximately $50,000. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 11.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Gain Therapeutics

Hedge funds have recently made changes to their positions in the company. Warberg Asset Management LLC purchased a new position in shares of Gain Therapeutics during the second quarter valued at $66,000. Renaissance Technologies LLC increased its position in Gain Therapeutics by 154.2% during the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after purchasing an additional 72,000 shares during the period. Finally, Hohimer Wealth Management LLC purchased a new position in Gain Therapeutics during the 2nd quarter valued at about $422,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.